Swedish Orphan Biovitrum – iF! - Inovativna farmaceutska inicijativa

About Us

Association

Mission and Vision

Strategy and Objectives

Organisational Structure

Statute of the Innovative Pharmaceutical Initiative

Business Ethics

Code of Conduct of Innovative Pharmaceutical Companies

Public Disclosures

iF! Members Disclosures

Financial reports

Frequently Asked Questions

Strategic Projects

HeMED

Serialization of medicines / NMVO

Clinical practice guidelines and monitoring treatment outcomes

Initiatives

WeWontRest

Treatment Outcomes 2020/30

Clinical trials

Useful Links

Useful links list

Source of information on vaccines and vaccination

Members

News

02/2026

The question is not whether we can afford to invest in health. The question is – can we afford not to?

Interview with Schalk Opperman, GM/MD at Merck Croatia & Slovenia...

02/2026

It is time for open dialogue and concrete steps towards a more efficient and more resilient system

Interview with Lana Kuzik Ileš, Country Manager, Bayer Croatia...

01/2026

The future will bring the development of personalised medicine, the use of advanced therapies, and even more intensive digitalisation of healthcare

Interview with Nataša Jenčić, general manager at Biogen...

Innovative Pharmaceutical Initiative – iF!

Florijana Andrašeca 20, 10000 Zagreb, Croatia

+385 1 2020 434

19

innovative pharmaceutical companies

703

employees

56

% of the Croatian medicines market

32

M Eur of transferred value in 2024

30

years of the Association’s activity

Homepage

> Members

> Swedish Orphan Biovitrum

Company title

Swedish Orphan Biovitrum

/ Swedish Orphan Biovitrum s.r.o. (SOBI)

Headquarters

Croatia office headquarters

Ulica Matka Baštijana 54, 10 000 Zagreb

Croatia office contact

Croatia number of employees

3

Therapeutic areas

–

Haematology

–

Immunology

–

Specialist care

Company claim

"Rare strength."

Company URL

Members

19

innovative pharmaceutical companies

703

employees

56

% of the Croatian medicines market

32

M Eur of transferred value in 2024

30

years of the Association’s activity